| Stereochemistry | ABSOLUTE |
| Molecular Formula | C72H116O4 |
| Molecular Weight | 1045.689 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 3 / 3 |
| E/Z Centers | 9 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
CCCCCCCCCCCCCCCC(=O)O[C@@H]1CC(C)=C(\C=C\C(C)=C\C=C\C(C)=C\C=C\C=C(C)\C=C\C=C(C)\C=C\[C@H]2C(C)=C[C@@H](CC2(C)C)OC(=O)CCCCCCCCCCCCCCC)C(C)(C)C1
InChI
InChIKey=YHGJHDJZIOYZIR-URPSFYETSA-N
InChI=1S/C72H116O4/c1-13-15-17-19-21-23-25-27-29-31-33-35-37-49-69(73)75-65-55-63(7)67(71(9,10)57-65)53-51-61(5)47-41-45-59(3)43-39-40-44-60(4)46-42-48-62(6)52-54-68-64(8)56-66(58-72(68,11)12)76-70(74)50-38-36-34-32-30-28-26-24-22-20-18-16-14-2/h39-48,51-55,65-67H,13-38,49-50,56-58H2,1-12H3/b40-39+,45-41+,46-42+,53-51+,54-52+,59-43+,60-44+,61-47+,62-48+/t65-,66+,67-/m0/s1
Xantofyl palmitate (brand name Adaptinol) is an approved drug for retinitis pigmentosa in Japan since August 1956. Adaptinol promotes aerobic metabolism of the retina to expand visual field or delay the development of narrowing of visual field. It also acts on the retina to improve vision in the dark.
It is usually used to transiently improve visual field and dark adaptation in patients with retinitis pigmentosa.
Originator
Approval Year
PubMed
Patents
ACTIVE MOIETY
